Scotia Capital Inc. increased its position in shares of Danaher Co. (NYSE:DHR) by 42.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 44,278 shares of the conglomerate’s stock after purchasing an additional 13,245 shares during the quarter. Scotia Capital Inc.’s holdings in Danaher were worth $4,110,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in Danaher by 4.6% during the fourth quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock worth $3,804,169,000 after purchasing an additional 1,789,474 shares during the last quarter. Parnassus Investments CA boosted its holdings in Danaher by 0.3% during the third quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after purchasing an additional 29,381 shares during the last quarter. Flossbach Von Storch AG boosted its holdings in Danaher by 17.2% during the third quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after purchasing an additional 994,902 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Danaher by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 6,263,971 shares of the conglomerate’s stock worth $580,150,000 after purchasing an additional 167,442 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Danaher by 1.4% during the third quarter. Dimensional Fund Advisors LP now owns 4,630,035 shares of the conglomerate’s stock worth $397,144,000 after purchasing an additional 63,327 shares during the last quarter. Institutional investors and hedge funds own 77.83% of the company’s stock.
Danaher Co. (NYSE DHR) traded down $0.62 during midday trading on Wednesday, hitting $102.18. 1,510,000 shares of the stock traded hands, compared to its average volume of 2,870,000. Danaher Co. has a one year low of $78.97 and a one year high of $104.82. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $71,280.00, a price-to-earnings ratio of 29.19, a P/E/G ratio of 2.17 and a beta of 1.04.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the firm posted $1.05 earnings per share. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. equities research analysts expect that Danaher Co. will post 4.37 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Thursday, March 29th will be given a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $0.64 annualized dividend and a dividend yield of 0.63%. This is a positive change from Danaher’s previous quarterly dividend of $0.14. Danaher’s payout ratio is 16.00%.
Several research analysts recently weighed in on DHR shares. Argus boosted their price target on shares of Danaher from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, February 1st. Cowen reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Danaher in a research report on Tuesday, January 30th. Credit Suisse Group reaffirmed an “outperform” rating on shares of Danaher in a research report on Friday, March 9th. Robert W. Baird reaffirmed a “buy” rating and issued a $99.00 price objective on shares of Danaher in a research report on Friday, December 15th. Finally, Citigroup lifted their price objective on shares of Danaher to $107.00 and gave the stock a “buy” rating in a research report on Friday, December 15th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Danaher currently has a consensus rating of “Buy” and an average price target of $101.40.
In related news, SVP Angela S. Lalor sold 42,988 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the sale, the senior vice president now owns 82,008 shares of the company’s stock, valued at approximately $8,388,598.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP William K. Daniel sold 131,066 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the sale, the executive vice president now directly owns 270,523 shares in the company, valued at approximately $27,606,872.15. The disclosure for this sale can be found here. In the last three months, insiders sold 313,260 shares of company stock worth $31,657,786. Insiders own 12.20% of the company’s stock.
WARNING: This piece of content was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/danaher-co-dhr-shares-bought-by-scotia-capital-inc.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.